SEARCH:   Advanced

Blood, 15 November 2006, Vol. 108, No. 10, pp. 3289-3294. Prepublished online as a Blood First Edition Paper on July 27, 2006; DOI 10.1182/blood-2006-05-022962. This Article Full Text Full Text (PDF) All Versions of this Article: blood-2006-05-022962v1 108/10/3289    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Attal, M. Articles by Facon, T. Search for Related Content PubMed PubMed Citation Articles by Attal, M. Articles by Facon, T. Related Collections Neoplasia Free Research Articles Clinical Trials and Observations Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS Maintenance therapy with thalidomide improves survival in patients with multiple myeloma Michel Attal, Jean-Luc Harousseau, Serge Leyvraz, Chantal Doyen, Cyrille Hulin, Lofti Benboubker, Ibrahim Yakoub Agha, Jean-Henri Bourhis, Laurent Garderet, Brigitte Pegourie, Charles Dumontet, Marc Renaud, Laurent Voillat, Christian Berthou, Gerald Marit, Mathieu Monconduit, Denis Caillot, Bernard Grobois, Herve Avet-Loiseau, Philippe Moreau, Thierry Facon, for the Inter-Groupe Francophone du Myélome (IFM) From the Department of Hematology, Hôpital Purpan, Toulouse, France; the Department of Biostatistics, Hôpital Purpan, Toulouse, France; the Hôtel Dieu, Nantes, France; the Centre Hospitalier Universitaire, Lausanne, Switzerland; the Cliniques Universitaires de Mont-Godinne, Yvoir, Belgium; the Centre Hospitalier Brabois, Nancy, France; the Hôpital Bretonneau, Tours, France; the Hôpital C. Huriez, Lille, France; the Institut Gustave Roussy, Villejuif, France; the Hôpital St-Antoine, Paris, France; the Hôpital Albert Michallon, Grenoble, France; the Hôpital Edouard Herriot, Lyon, France; the Centre Hospitalier la Mileterie, Poitiers, France; the Hôpital Jean Minjoz, Besançon, France; the Hôpital A. Morvan, Brest, France; the Hôpital Haut-Lévèque, Bordeaux Pessac, France; the Centre Henri Becquerel, Rouen, France; the Centre Hospitalier Le Bocage, Dijon, France; and the Hôpital Sud, Rennes, France. Newer chemotherapeutic protocols as well as high-dose chemotherapy have increased the response rate in myeloma. However, these treatments are not curative. Effective maintenance strategies are now required to prolong the duration of response. We conducted a randomized trial of maintenance treatment with thalidomide and pamidronate. Two months after high-dose therapy, 597 patients younger than age 65 years were randomly assigned to receive no maintenance (arm A), pamidronate (arm B), or pamidronate plus thalidomide (arm C). A complete or very good partial response was achieved by 55% of patients in arm A, 57% in arm B, and 67% in arm C (P = .03). The 3-year postrandomization probability of event-free survival was 36% in arm A, 37% in arm B, and 52% in arm C (P < .009). The 4-year postdiagnosis probability of survival was 77% in arm A, 74% in arm B, and 87% in arm C (P < .04). The proportion of patients who had skeletal events was 24% in arm A, 21% in arm B, and 18% in arm C (P = .4). Thalidomide is an effective maintenance therapy in patients with multiple myeloma. Maintenance treatment with pamidronate does not decrease the incidence of bone events. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Exciting new agents in multiple myeloma Giampaolo Merlini Blood 2006 108: 3235-3236. [Full Text] [PDF] This article has been cited by other articles: A. Palumbo, F. Gay, P. Falco, C. Crippa, V. Montefusco, F. Patriarca, F. Rossini, S. Caltagirone, G. Benevolo, N. Pescosta, et al. Bortezomib As Induction Before Autologous Transplantation, Followed by Lenalidomide As Consolidation-Maintenance in Untreated Multiple Myeloma Patients J. Clin. Oncol., February 10, 2010; 28(5): 800 - 807. [Abstract] [Full Text] [PDF] H. Ludwig, M. Beksac, J. Blade, M. Boccadoro, J. Cavenagh, M. Cavo, M. Dimopoulos, J. Drach, H. Einsele, T. Facon, et al. Current Multiple Myeloma Treatment Strategies with Novel Agents: A European Perspective Oncologist, January 1, 2010; 15(1): 6 - 25. [Abstract] [Full Text] [PDF] A. K. Stewart, P. G. Richardson, and J. F. San-Miguel How I treat multiple myeloma in younger patients Blood, December 24, 2009; 114(27): 5436 - 5443. [Abstract] [Full Text] [PDF] S. K. Kumar, J. R. Mikhael, F. K. Buadi, D. Dingli, A. Dispenzieri, R. Fonseca, M. A. Gertz, P. R. Greipp, S. R. Hayman, R. A. Kyle, et al. Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines Mayo Clin. Proc., December 1, 2009; 84(12): 1095 - 1110. [Abstract] [Full Text] [PDF] M. Cavo, L. Pantani, P. Tacchetti, M. C. Pallotti, A. Brioli, A. Petrucci, E. Zamagni, and P. Tosi Thalidomide Maintenance in Multiple Myeloma: Certainties and Controversies J. Clin. Oncol., November 10, 2009; 27(32): e186 - e187. [Full Text] [PDF] A. Spencer, H. M. Prince, and A. W. Roberts Reply to M. Cavo J. Clin. Oncol., November 10, 2009; 27(32): e188 - e188. [Full Text] [PDF] M. Cavo, F. Di Raimondo, E. Zamagni, F. Patriarca, P. Tacchetti, A. F. Casulli, S. Volpe, G. Perrone, A. Ledda, M. Ceccolini, et al. Short-Term Thalidomide Incorporated Into Double Autologous Stem-Cell Transplantation Improves Outcomes in Comparison With Double Autotransplantation for Multiple Myeloma J. Clin. Oncol., October 20, 2009; 27(30): 5001 - 5007. [Abstract] [Full Text] [PDF] J.-L. Harousseau, M. Attal, and H. Avet-Loiseau The role of complete response in multiple myeloma Blood, October 8, 2009; 114(15): 3139 - 3146. [Abstract] [Full Text] [PDF] J. K Kettle, K. L Finkbiner, S. E Klenke, R. D Baker, D. W Henry, and C. B Williams Initial therapy in multiple myeloma: investigating the new treatment paradigm Journal of Oncology Pharmacy Practice, September 1, 2009; 15(3): 131 - 141. [Abstract] [PDF] S. Kumar, S. Giralt, E. A. Stadtmauer, J. L. Harousseau, A. Palumbo, W. Bensinger, R. L. Comenzo, S. Lentzsch, N. Munshi, R. Niesvizky, et al. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens Blood, August 27, 2009; 114(9): 1729 - 1735. [Abstract] [Full Text] [PDF] I. I. van Gameren, M. H. van Rijswijk, J. Bijzet, E. Vellenga, and B. P. Hazenberg Histological regression of amyloid in AL amyloidosis is exclusively seen after normalization of serum free light chain Haematologica, August 1, 2009; 94(8): 1094 - 1100. [Abstract] [Full Text] [PDF] E. Terpos, O. Sezer, P. I. Croucher, R. Garcia-Sanz, M. Boccadoro, J. San Miguel, J. Ashcroft, J. Blade, M. Cavo, M. Delforge, et al. The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network Ann. Onc., August 1, 2009; 20(8): 1303 - 1317. [Abstract] [Full Text] [PDF] M. A. Hussein, V. Bolejack, J. A. Zonder, B. G.M. Durie, A. J. Jakubowiak, J. J. Crowley, and B. Barlogie Phase II Study of Thalidomide Plus Dexamethasone Induction Followed by Tandem Melphalan-Based Autotransplantation and Thalidomide-Plus-Prednisone Maintenance for Untreated Multiple Myeloma: A Southwest Oncology Group Trial (S0204) J. Clin. Oncol., July 20, 2009; 27(21): 3510 - 3517. [Abstract] [Full Text] [PDF] D. Reece, K. W. Song, T. Fu, B. Roland, H. Chang, D. E. Horsman, A. Mansoor, C. Chen, E. Masih-Khan, Y. Trieu, et al. Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13 Blood, July 16, 2009; 114(3): 522 - 525. [Abstract] [Full Text] [PDF] S. Giralt, D. H. Vesole, G. Somlo, A. Krishnan, E. Stadtmauer, P. Mccarthy, M. C. Pasquini;, and on behalf of the Blood and Marrow Transplant Clini Re: Tandem vs Single Autologous Hematopoietic Cell Transplantation for the Treatment of Multiple Myeloma: A Systematic Review and Meta-analysis J Natl Cancer Inst, July 1, 2009; 101(13): 964 - 964. [Full Text] [PDF] G. Tricot, S. E. Kern, and B. Barlogie Re: Tandem vs Single Autologous Hematopoietic Cell Transplantation for the Treatment of Multiple Myeloma: A Systematic Review and Meta-analysis J Natl Cancer Inst, July 1, 2009; 101(13): 964 - 966. [Full Text] [PDF] J.-L. Harousseau and P. Moreau Autologous Hematopoietic Stem-Cell Transplantation for Multiple Myeloma N. Engl. J. Med., June 18, 2009; 360(25): 2645 - 2654. [Full Text] [PDF] J.-L. Harousseau, M. Dreyling, and On behalf of the ESMO Guidelines Working Group Multiple myeloma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up Ann. Onc., May 1, 2009; 20(suppl_4): iv97 - iv99. [Full Text] [PDF] A. Spencer, H. M. Prince, A. W. Roberts, I. W. Prosser, K. F. Bradstock, L. Coyle, D. S. Gill, N. Horvath, J. Reynolds, and N. Kennedy Consolidation Therapy With Low-Dose Thalidomide and Prednisolone Prolongs the Survival of Multiple Myeloma Patients Undergoing a Single Autologous Stem-Cell Transplantation Procedure J. Clin. Oncol., April 10, 2009; 27(11): 1788 - 1793. [Abstract] [Full Text] [PDF] A. K. Stewart Reduced-intensity allogeneic transplantation for myeloma: reality bites Blood, April 2, 2009; 113(14): 3135 - 3136. [Full Text] [PDF] J. F. San-Miguel and M.-V. Mateos How to treat a newly diagnosed young patient with multiple myeloma Hematology, January 1, 2009; 2009(1): 555 - 565. [Abstract] [Full Text] [PDF] A. Palumbo and F. Gay How to treat elderly patients with multiple myeloma: combination of therapy or sequencing Hematology, January 1, 2009; 2009(1): 566 - 577. [Abstract] [Full Text] [PDF] I. M. Ghobrial and A. K. Stewart ASH evidence-based guidelines: what is the role of maintenance therapy in the treatment of multiple myeloma? Hematology, January 1, 2009; 2009(1): 587 - 589. [Abstract] [Full Text] [PDF] G. Tricot Is more better in myeloma? Blood, November 1, 2008; 112(9): 3532 - 3532. [Full Text] [PDF] A. Dispenzieri Biology, treatment, and time Blood, October 15, 2008; 112(8): 2999 - 3000. [Full Text] [PDF] J. San-Miguel, J.-L. Harousseau, D. Joshua, and K. C. Anderson Individualizing Treatment of Patients With Myeloma in the Era of Novel Agents J. Clin. Oncol., June 1, 2008; 26(16): 2761 - 2766. [Abstract] [Full Text] [PDF] A. Palumbo, F. Gay, S. Bringhen, A. Falcone, N. Pescosta, V. Callea, T. Caravita, F. Morabito, V. Magarotto, M. Ruggeri, et al. Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma Ann. Onc., June 1, 2008; 19(6): 1160 - 1165. [Abstract] [Full Text] [PDF] H. M. Lazarus, G. L. Phillips, R. H. Herzig, D. D. Hurd, S. N. Wolff, and G. P. Herzig High-Dose Melphalan and the Development of Hematopoietic Stem-Cell Transplantation: 25 Years Later J. Clin. Oncol., May 10, 2008; 26(14): 2240 - 2243. [Full Text] [PDF] A. Palumbo, T. Facon, P. Sonneveld, J. Blade, M. Offidani, F. Gay, P. Moreau, A. Waage, A. Spencer, H. Ludwig, et al. Thalidomide for treatment of multiple myeloma: 10 years later Blood, April 15, 2008; 111(8): 3968 - 3977. [Abstract] [Full Text] [PDF] J. Mehta One or two autografts for myeloma? Blood, April 1, 2008; 111(7): 3899 - 3900. [Full Text] [PDF] R. A. Kyle and S. V. Rajkumar Multiple myeloma Blood, March 15, 2008; 111(6): 2962 - 2972. [Abstract] [Full Text] [PDF] A. Abdelkefi, S. Ladeb, L. Torjman, T. B. Othman, A. Lakhal, N. B. Romdhane, H. E. Omri, M. Elloumi, H. Belaaj, R. Jeddi, et al. Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial Blood, February 15, 2008; 111(4): 1805 - 1810. [Abstract] [Full Text] [PDF] W. Bensinger Stem-Cell Transplantation for Multiple Myeloma in the Era of Novel Drugs J. Clin. Oncol., January 20, 2008; 26(3): 480 - 492. [Abstract] [Full Text] [PDF] H. M. Lokhorst, I. Schmidt-Wolf, P. Sonneveld, B. van der Holt, H. Martin, R. Barge, U. Bertsch, J. Schlenzka, G. M.J. Bos, S. Croockewit, et al. Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma Haematologica, January 1, 2008; 93(1): 124 - 127. [Abstract] [Full Text] [PDF] J. A. Katzel, P. Hari, and D. H. Vesole Multiple Myeloma: Charging Toward a Bright Future CA Cancer J Clin, September 1, 2007; 57(5): 301 - 318. [Abstract] [Full Text] [PDF] ASCO 2007 Clinical Practice Guideline Update on the Role of Bisphosphonates in Multiple Myeloma: Guideline Summary J. Oncol. Pract, July 1, 2007; 3(4): 236 - 236. [Full Text] [PDF] M. Cavo, P. Tosi, E. Zamagni, C. Cellini, P. Tacchetti, F. Patriarca, F. Di Raimondo, E. Volpe, S. Ronconi, D. Cangini, et al. Prospective, Randomized Study of Single Compared With Double Autologous Stem-Cell Transplantation for Multiple Myeloma: Bologna 96 Clinical Study J. Clin. Oncol., June 10, 2007; 25(17): 2434 - 2441. [Abstract] [Full Text] [PDF] R. A. Kyle, G. C. Yee, M. R. Somerfield, P. J. Flynn, S. Halabi, S. Jagannath, R. Z. Orlowski, D. G. Roodman, P. Twilde, and K. Anderson American Society of Clinical Oncology 2007 Clinical Practice Guideline Update on the Role of Bisphosphonates in Multiple Myeloma J. Clin. Oncol., June 10, 2007; 25(17): 2464 - 2472. [Abstract] [Full Text] [PDF] C. Carlo-Stella, A. Guidetti, M. Di Nicola, C. Lavazza, L. Cleris, D. Sia, P. Longoni, M. Milanesi, M. Magni, Z. Nagy, et al. IFN-{gamma} Enhances the Antimyeloma Activity of the Fully Human Anti-Human Leukocyte Antigen-DR Monoclonal Antibody 1D09C3 Cancer Res., April 1, 2007; 67(7): 3269 - 3275. [Abstract] [Full Text] [PDF] B. G. M. Durie and IMWG Use of Bisphosphonates in Multiple Myeloma: IMWG Response to Mayo Clinic Consensus Statement Mayo Clin. Proc., April 1, 2007; 82(4): 516 - 517. [Full Text] [PDF] M. Q. Lacy, S. V. Rajkumar, and Mayo Clinic Myeloma Group Use of Bisphosphonates in Multiple Myeloma: IMWG Response to Mayo Clinic Consensus Statement-Reply-I Mayo Clin. Proc., April 1, 2007; 82(4): 517 - 518. [Full Text] [PDF] R. Fonseca and A. K. Stewart Targeted therapeutics for multiple myeloma: The arrival of a risk-stratified approach Mol. Cancer Ther., March 1, 2007; 6(3): 802 - 810. [Abstract] [Full Text] [PDF] A. Dispenzieri, S. V. Rajkumar, M. A. Gertz, M. Q. Lacy, R. A. Kyle, P. R. Greipp, T. E. Witzig, J. A. Lust, S. J. Russell, S. R. Hayman, et al. Treatment of Newly Diagnosed Multiple Myeloma Based on Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART): Consensus Statement Mayo Clin. Proc., March 1, 2007; 82(3): 323 - 341. [Abstract] [Full Text] [PDF] M. Attal, P. Moreau, H. Avet-Loiseau, and J.-L. Harousseau Stem Cell Transplantation in Multiple Myeloma Hematology, January 1, 2007; 2007(1): 311 - 316. [Abstract] [Full Text] [PDF]

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020